Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KARISMA: intravenous cipargamin in severe Plasmodium falciparum malaria
PACTR202102626263606Phase 2Recruiting
- Sponsor
- Novartis
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 2, open-label trial of cipargamin in Malaria (2 arms), sponsored by Novartis. Primary endpoint: Percentage of participants achieving at least 90% reduction in Plasmodium falciparum at 12 hours. Started Jun 2021; status: recruiting.
02
Drugs
cipargamin
03
Conditions
Malaria
Beyond the preview
Go deeper on PACTR202102626263606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202102626263606.